IPG Photonics shares fall 2.47% intraday after AcCELLerated Biologics announced distribution agreement for RegenaLase™ Laser System.

IPG Photonics Corporation declined 2.47% intraday, with the company announcing an exclusive agreement with IPG Medical Corporation, a wholly owned subsidiary of IPG Photonics Corporation, to distribute the RegenaLase™ Laser System throughout the United States. This new dual-wavelength laser platform is engineered to treat musculoskeletal soft tissue, including meniscus cartilage and inflammation. The RegenaLase system features two advanced laser modalities: a 1550 nm erbium fiber laser for minimally invasive cartilage surgery and a 980 nm diode laser for non-invasive photobiomodulation therapy. This dual functionality enables physicians to provide both in-office pain relief and advanced cartilage treatment — all from a single, compact, and versatile device.